Articles related to BLADDER CANCER

“The SunRISe-2 trial was stopped in advance for futility based on week-18 overall response rate assessment and the totality of the efficacy data. However, the CR rates in both arms are compelling.” — Andrea Necchi, MD, ASCO GU Symposium 2026

“We’re lucky to have found it at this stage where I could say the word cure, because I don’t use that word lightly as a cancer doctor.” – Dr. Janet Kukreja, the Director of Urologic Oncology at the CU Cancer Center/UC Health University of Colorado Hospital

“Controlling cancer is, of course, the goal, but there must also be a greater emphasis on life after treatment.”

Company leadership demands FDA explanation for approving identical treatment in patients with CIS while refusing filing for those without CIS, despite same trial data showing comparable clinical benefits and safety profiles.

Workplace exposure to harmful chemicals remains a significant risk factor for bladder cancer, particularly affecting specific occupations and requiring targeted prevention strategies.

The TROPiCs-04 trial results challenge the current treatment landscape for metastatic urothelial carcinoma, highlighting the need for new strategies post-relapse and the importance of next-generation sequencing in patient selection.